AXL and cancer: Cancer cell lines with BRAF mutations did not show as high correlation between AXL overexpression and RIPK3 as those with wild-type BRAF, suggesting that oncogenic pressure from either BRAF or AXL is sufficient to promote RIPK3 expression loss, and escape from necroptosis in cancer (S7 Fig).